Salute e Benessere

dsm-firmenich completes acquisition of postbiotics pioneer Adare Biome

About Adare BiomeAdare Biome develops, produces, and commercializes high-quality postbiotic solutions, including its pharmaceutical product, Lactéol®, which is marketed in almost 40 countries around the world. Its ingredients, including LBiome™ and LBiotix™, are used for digestive health applications in human, pet, and production animals. Adare Biome is based in Houdan, France. More information can be found at www.adarebiome.com. About Adare Biome Adare Biome develops, produces, and...

Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional…

Press Release Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress NCX 470 0.1% showed up to 1.73mmHg greater mean diurnal intraocular pressure (IOP) reduction from baseline than latanoprost in the adaptive dose selection period of the Phase 3 Mont Blanc trialNCX 470 demonstrated a statistically greater proportion of subjects with 10 mmHg or more...

BioSenic S.A. : Information on the total number of voting rights and shares

REGULATED INFORMATION Mont-Saint-Guibert, Belgium, July 3 rd, 2023, 7.00 am CEST – BIOSENIC(Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in in the areas of innate immunity, inflammation and organ/function repair, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares following the conversion of convertible bonds (CBs). The following information is published in accordance with...

FHC Shanghai Global Food Trade Show to be renewed and upgraded to 10 exhibit…

Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd. has accumulated more than 30 years of exhibition experience. After 26 years, FHC Shanghai Global Food Trade Show has become one of the leading exhibitions in the food, beverage and catering industry, while enabling the rapid growth of Sinoexpo's food and beverage sectors. At the same time, it is also one of Informa Markets hotel catering and food series global exhibitions. Shanghai Sinoexpo Informa Markets International…

Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian…

Dr. Ibrahim Aljufalli, Chairman of the Lifera Board, said: "This strategic collaboration is a reflection of Lifera's mission to grow Saudi Arabia's biopharma sector. With CENTOGENE's expertise in the field of rare, metabolic and neurodegenerative diseases, we see tremendous potential value for the JV to provide more timely and accurate diagnoses which are crucial to patients and their families, driven by a comprehensive diagnostic portfolio that goes beyond standard laboratory testing and…

Spanish Medical Skincare Trailblazer mesoestetic Kicks Off 2023 Road Show in…

The chosen venue, Xie Zilong Photography Museum, was founded by Mr. Xie Zilong, who is also well-known for establishing LBX Pharmacy, a prominent Chinese pharmacy chain. Interestingly, Mr. Xie had similar background with mesoestetic's founder, Juan Carlos Font Más, who utilized his pharmacological knowledge to create personalized beauty skincare formulas and opened his pharmacy in Barcelona during the early 1980s. Both men share a passion for medicine, art, and antique painting collections. By…

Orexo wins patent litigation for ZUBSOLV® in the US

Nikolaj Sørensen, President and CEO of Orexo AB, said: "I am very pleased that me and my team in both the US and Sweden, yet another time have received confirmation about the strength of our patents protecting the innovation and technology behind ZUBSOLV®. Since its launch in the US in 2013, ZUBSOLV® has generated more than SEK 4.7 billion in net revenues and will continue to be an important cash generator. I want to thank all our shareholders and, most importantly, the employees for their…

Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation…

Hyrimoz ®(adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab HCF biosimilars approved in the US, Hyrimoz HCF expands access for millions of people with serious inflammatory diseasesLaunch builds upon Sandoz global biosimilars legacy, with Hyrimoz 50 mg/mLhaving nearly 120 million days of patient experience across 41 countries 1Basel, July 1, 2023–...

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in…

Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma ®(onasemnogene abeparvovec)Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatment experienceCAMBRIDGE, Mass., June30, 2023(GLOBE NEWSWIRE) --Biogen Inc. (Nasdaq: BIIB) announced new SPINRAZA ®(nusinersen) data aimed at answering critical questions for the spinal muscular...

MDxHealth Announces Results of its Extraordinary General Shareholders' Meeting

NEWS RELEASE - REGULATED INFORMATION 30 June 2023 , 10:00 p.m. CESTMDxHealth Announces Resultsof its Extraordinary General Shareholders' MeetingIRVINE, CA, and HERSTAL, BELGIUM– 30 June 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (" mdxhealth " or the " Company "), a commercial-stage precision diagnostics company, today held an extraordinary general shareholders' meeting (" EGM ").The items on the agenda of the EGM included...

Groupe Casino : Partnership proposal between Casino group and Prosol

Partnership proposal between Casino group and Prosol Paris, 30 June 2023Casino group and Prosol announce that they have entered into a memorandum of understanding relating to a major strategic partnership under which Prosol would implement its "Fresh" concept, which it has developed with success, in Casino's hypermarkets and supermarkets and certain stores under the Monoprix brand.This partnership will leverage the Prosol Group's unrivalled expertise in fresh produce (fruit and...

State of Oregon Ambulance Service Market to Exhibit 3.7% CAGR and Generate…

As per the report published by Research Dive, the state of Oregon ambulance service market is expected to register a revenue of $429.4 million by 2031, at a CAGR of 3.7% during the forecast period 2022-2031. As per the report published by Research Dive, thestate ofOregonambulance service market is expected to register a revenue of$429.4 millionby 2031, at a CAGR of 3.7% during the forecast period 2022-2031. Segments of the State of Oregon Ambulance Service Market The...

Four-year follow up data for Roche's Evrysdi show continued increase in number…

Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children with Type 1 SMANinety-one percent of children were alive at month 48More than 95% maintained the ability to swallow - without treatment they would have required feeding support and majority would have died within 2 yearsEvrysdi is now approved in 99 countries with more than 8,500 patients treated globallyBasel, 30 June 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY)...

CRISPR Market worth $7.1 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134401204 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134401204 Browse in-depth TOC on "CRISPR Market" 39 - Tables 38 - Figures 170 - Pages CRISPR Market Scope: CRISPR products accounted for the largest share of the CRISPR market Among the products & services, the CRISPR market is segmented into CRISPR products, and CRISPR...

Total number of shares and voting rights in Zealand Pharma at June 30, 2023

Company announcement – No. 26 / 2023 Total number of shares and voting rights in Zealand Pharma at June 30, 2023 Copenhagen, Denmark, June 30, 2023–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of...

Revenue Cycle Management Market worth $84.1 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153900104 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153900104 Browse in-depth TOC on "Revenue Cycle Management Market" 282 - Tables 40 - Figures 275 - Pages Revenue Cycle Management Market Scope: By product & services segment, the outsourcing services segment is expected to grow at the highest growth rate during the forecast...

Feedback Digest from Global Consultation on Ecosystem Restoration Standard

Ecosystem Restoration Standard (ERS) released a summary of the feedback following the successful completion of its public consultation.Launched on March 21st, ERS public consultation has exceeded expectations, drawing substantial participation from 554 organizations around the globe.Thibault Sorret, ERS CEO, explains: “We're thrilled by the response to the public consultation. Not only in the number of responses but also in their depth and quality. We're in the midst of integrating...

New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and…

BIOVAXYS ANNOUNCES MANAGEMENT CHANGE

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company based in Vacouver, Canada, is the exclusive US licensee and distributor of a portfolio of OTC female reproductive health products currently marketed in the EU from Barcelona-based Procare Health Iberia, and is also entering clinical development for BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late stage ovarian cancer…

Novartis signs agreement to divest 'front of eye' ophthalmology assets in line…

Divested assets to includeXiidra ® , on-market treatment for dry eye disease andSAF312 (libvatrep),potential therapy for chronic ocular surface painDeal consistent with Novartis focused strategy of prioritized therapeutic areas Closing anticipated 2H 2023, subject to customary conditions Basel, June 30, 2023— Novartis announced today that it has signed an agreement to divest 'front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company, in a...

CJ FNT Unveils 'TasteNrich® HYBIND', a Natural Phosphate Replacement Solution

TasteNrich® HYBIND emerges as a viable alternative to conventional phosphates, which have long been employed to enhance texture, and moisture retention in processed meats. However, concerns over their potential health risks especially for the juvenile have triggered the need for more natural and efficient alternatives in Europe. TasteNrich® HYBINDemerges as a viable alternative to conventional phosphates, which have long been employed to enhance texture, and moisture retention in processed…

Devyser has inaugurated its CLIA-certified laboratory and performed the first…

The laboratory will scale as demand grows and will initially focus on providing clinical testing services for healthcare providers and patients in the US. Devyser is currently working on reimbursement for each of the tests that will be part of the CLIA-certified laboratory test offering. The laboratory will scale as demand grows and will initially focus on providing clinical testing services for healthcare providers and patients in the US. Devyser is currently working on reimbursement for…

Univercells Technologies Acquired by Donaldson Company

"I am proud of the achievements of our team during this journey with Univercells and Gamma Biosciences, as we ramped-up our development, production and service capabilities and continued to innovate and launch novel products," said Mathias Garny, CEO of UT. "We are now looking forward to this new era with Donaldson to further strengthen our market position and deliver robust, end-to-end biomanufacturing solutions to our customers as they advance towards commercialization of…

Vistin Pharma ASA: Offer to buy back shares

30 June 2023: Vistin Pharma ASA (the “Company”) has decided to launch an offer to all shareholders in the Company to buy back up to 250,000 shares in the Company in connection with its Long Term Incentive Plan (LTIP) for the executive management. The executive management can in accordance with the LTIP purchase shares for up to MNOK 6, at a 25% discount, with three years of binding time. The buyback will be conducted as a reverse book-building process in which shareholders can submit sales...

Altri Comunicati